FORM 4

BIOMARIN PHARMACEUTICAL INC - BMRN

Filed: September 28, 2018 (period: September 27, 2018)

Statement of changes in beneficial ownership of securities
**FORM 4**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

_Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940._

1. Name and Address of Reporting Person

   LAWLIS V BRYAN

   (Last) (First) (Middle)

   C/O BIOMARIN PHARMACEUTICAL INC.

   105 DIGITAL DRIVE

   (Street)

   NOVATO CA 94949

   (City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

   BIOMARIN PHARMACEUTICAL INC [ BMRN ]

3. Date of Earliest Transaction (Month/Day/Year)

   09/27/2018

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

   (Check all applicable)

   X Director 10% Owner

   Officer (give title below)

   Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

   X Form filed by One Reporting Person

   Form filed by More than One Reporting Person

---

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>09/27/2018(1)</td>
<td></td>
<td>M</td>
<td>2,150 A</td>
<td>$14.39 21,310 D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common Stock</td>
<td>09/27/2018(1)</td>
<td></td>
<td>S</td>
<td>2,150 D</td>
<td>$97.93 19,160 D</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
</table>

Explanation of Responses:

1. Trade made pursuant to a 1085-1 plan executed on June 12, 2018.
2. Reflects the number of options outstanding after the transactions from this specific stock option grant.

**/s/ Eric Fleekop, Attorney-in-Fact** 09/28/2018

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.